Search clinical trials for: Apatinib plus Camrelizumab

Total 7176 results

Nanfang Hospital of Southern Medical University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

Hepatocellular Carcinoma

China
Peking University First Hospital

Not yet recruiting

Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors

Immunotherapy | SBRT | Bulky Tumor
Bristol-Myers Squibb
PPD; ICON Clinical Research; Q2 Solutions; Molecular MD; MultiPharma; Steering Committee and other collaborators

Completed

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

Chronic Phase Chronic Myeloid Leukemia

Italy, Thailand, United States, Belgium, Czechia, Hungary, Argentina, Austria, Brazil, Canada, China, France, Korea, Republic of, Poland, Spain
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Spain, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Puerto Rico, Singapore, South Africa, Taiwan, United Kingdom, Australia, France, Philippines, Sweden, Thailand, Russian Federation, China, Poland, Finland, Isra... and more
ZHOU FANGJIAN
Pfizer

Recruiting

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Renal Cell Carcinoma | Neoadjuvant

China
Pfizer

Withdrawn

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Carcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
Wuhan University

Recruiting

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (SABRE)

Non-Small Cell Lung Cancer

China
Newcastle University
Bristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaborators

Completed

Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia (SPIRIT2)

Myeloid Leukemia, Chronic, Chronic Phase

United Kingdom
Bristol-Myers Squibb

Completed

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (DASISION)

Myeloid Leukemia, Chronic

Germany, India, Japan, Korea, Republic of, Turkey, Chile, China, Spain, Australia, France, Poland, Mexico, Colombia, Belgium, Austria, Italy, Peru, Greece, Brazil, Czech Republic, Hungary, Russian Federation, Netherlands, Argentina, Den... and more
Peking Union Medical College Hospital

Recruiting

The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.

Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Advanced Solid Tumor

China
Xingchen Peng
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC

Head and Neck Squamous Cell Carcinoma

China
University of California, San Francisco
Genentech, Inc.

Completed

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

Healthy

United States
University of Pittsburgh

Completed

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Head and Neck Cancer | Non Small Cell Lung Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Tianjin Medical University Cancer Institute and...

Recruiting

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma | HRD+Breast Cancer

China
Huazhong University of Science and Technology

Not yet recruiting

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Advanced or Metastatic EP-NEC

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Solid Tumor

China
Bart Neyns
Pfizer

Completed

A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (AxiGII)

Glioblastoma Multiforme

Belgium
Wuhan Union Hospital, China

Active, not recruiting

Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer

Rectal Cancer | Radiotherapy | Immunotherapy

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

PD-L1 Positive Non-small Cell Lung Cancer
Fudan University

Unknown

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Tumor

China
Pfizer

Completed

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Chronic Myeloid Leukaemia

Hungary
Bristol-Myers Squibb

Completed

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (START rollover)

Leukemia

Germany, Italy, Korea, Republic of, Sweden, Thailand, United States, Australia, France, Poland, Switzerland, Spain, Ireland, Peru, Brazil, South Africa, Canada, Argentina, Hungary, Finland, Israel, Norway, Russian Federation, United... and more
Sun Yat-sen University

Recruiting

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

Nasopharyngeal Carcinoma

China
Huazhong University of Science and Technology
The First Affiliated Hospital of Nanchang University

Recruiting

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

Lymphoma | Relapse/Recurrence

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Esophageal Squamous Cell Carcinoma | Progression to PD-1 Antibody

China
Elevar Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma

United States, Korea, Republic of
Shanghai Jiao Tong University Affiliated Sixth...

Unknown

A Phase II Study of Apatinib in STS Patients

Soft Tissue Sarcoma
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

CAR-T Cell | Ph Positive ALL | Dasatinib

China
UNC Lineberger Comprehensive Cancer Center

Completed

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous Leukemia

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

Advanced Solid Tumor
Zhejiang Cancer Hospital

Recruiting

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Brain Metastases | NSCLC Stage IV | Immunotherapy

China
National Taiwan University Hospital
GlaxoSmithKline

Completed

Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer

Metastatic Breast Cancer

Taiwan
Oslo University Hospital
The Research Council of Norway

Completed

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (MetAction)

Metastatic Cancer

Norway
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Breast Cancer | Triple Negative Breast Cancer

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients (CHANCE)

Oral Squamous Cell Carcinoma

China
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma

Cholangiocarcinoma
Sun Yat-sen University

Recruiting

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Masaryk University

Active, not recruiting

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia (HALF)

Chronic Myeloid Leukemia, Chronic Phase | Withdrawal;Drug

Czechia
Tianjin Medical University Cancer Institute and...

Unknown

Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer

China
Shanghai Jiao Tong University School of Medicine

Completed

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Oral Cancer | VEGFR2 Inhibitor | Programmed Cell Death 1 Inhibitor | Inductive Therapy

China
Sun Yat-sen University
Guangdong Provincial People's Hospital; Affiliated Cancer Hospital & Institute... and other collaborators

Recruiting

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Treatment of Carrying TP53 Harmful Mutations

Advanced Cancer

China
Fudan University

Recruiting

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Breast Cancer

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Camrelizumab Utilization on Patients With Advanced Liver Cancer

Advanced Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Cervical Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

The Efficacy and Safety of KN046 Combined With Axitinib

NSCLC

China
University Hospital, Bordeaux

Completed

Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors (EVAX)

Carcinoma, Renal Cell | Malignant Advanced Solid Tumors

France

Search clinical trials for: Apatinib plus Camrelizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations